Anzeige
Meldung des Tages: US-Goldprojekt vor dem Durchbruch: Warum Investoren jetzt aufmerksam werden

Soligenix News

Aktie
WKN:  A40DDP ISIN:  US8342236044 US-Symbol:  SNGX Branche:  Biotechnologie Land:  USA
1,145 $
+0,02 $
+1,78%
0,9739 € 21:03:49 Uhr
Depot/Watchlist
Marktkapitalisierung *
4,99 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Soligenix News

02.09.25 - PR Newswire
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire
18.08.25 - PR Newswire
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results PR Newswire
14.08.25 - PR Newswire
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results PR Newswire
06.08.25 - PR Newswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators PR Newswire
06.08.25 - PR Newswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators PR Newswire
04.08.25 - PR Newswire
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Late-​Stage Pipeline Wins Boost Investor Confidence in High-​Growth Therapeutic Areas PR Newswire
04.08.25 - PR Newswire
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Late-​Stage Pipeline Wins Boost Investor Confidence in High-​Growth Therapeutic Areas PR Newswire
31.07.25 - PR Newswire
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease PR Newswire
08.07.25 - PR Newswire
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones PR Newswire
01.07.25 - PR Newswire
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions PR Newswire
09.05.25 - PR Newswire
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results PR Newswire
14.04.25 - PR Newswire
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks PR Newswire

Newssuche

Videos

newspaper
07.04.26 +4,00%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »